Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Filter by Categories
BioBlast®
Biosimilars Deals 2023
Biosimilars Deals 2024
Diversity
Masterclasses
Other Podcasts
Other Updates
Our Awards
Patent Case Summaries
Patent Litigation
Patents
PipCast®
PTE
Trade Marks
Webinars

Home / News / BioBlast® / Biosimilar Deals 2020

EXPLORE OUR

Biosimilars Deals 2020

Explore our interactive biosimilar news updates, collating tailored reports by brand, INN, originator/biosimilar applicant, litigation, region, or date. Alternatively, review our weekly BioBlast updates below.

Xbrane Pharma announces agreement with Akademiska Hus for lease of premises

Xbrane Pharma announced that it has entered into an agreement with Akademiska Hus for the lease of new premises at Campus Solna. From March 2021, Xbrane will establish a new development lab for biosimilars and will move their headquarters to the new campus at Solna. Xbrane has said that the new development lab will give them expanded capacity and the ability to start development of additional biosimilar candidates.

AbbVie completes acquisition of Allergan

AbbVie announces it has completed its acquisition of Allergan, following regulatory approval from all relevant Government agencies. AbbVie will now have access to Allergan’s neuroscience products including Vraylar® and Ubrelvy®, and aesthetic products including the Botox® and Juvederm® brands.

Bausch + Lomb enter exclusive licensing agreement with STADA and Xbrane Biopharma

Bausch + Lomb announced it has entered into an exclusive licensing agreement with STADA and Xbrane Biopharma for the development and commercialisation of a ranibizumab biosimilar. Under the agreement, Xbrane and STADA will be jointly responsible for finalising development of the biosimilar, with Xbrane to provide commercial supply and Bausch + Lomb responsible for sales, marketing and all other commercialisation efforts.